Literature DB >> 12355036

Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report.

Susan M Begelman1, Steven R Deitcher.   

Abstract

Outpatient treatment of deep venous thrombosis has gained widespread acceptance and is facilitated by the use of subcutaneous low molecular weight heparins (LMWH). We report two patients in whom subcutaneous lepirudin was used for long term anticoagulation after heart transplant or surgical pulmonary embolectomy because treatment with LMWH or warfarin was contraindicated, unsuccessful, or impractical. Neither bleeding complications nor recurrent thromboses developed. Subcutaneous lepirudin may be safely and effectively employed for the outpatient treatment of venous thrombosis in selected cases including patients with heparin-induced thrombocytopenia and in those who fail LMWH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355036     DOI: 10.1023/a:1020435108773

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  10 in total

1.  Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature).

Authors:  A C Andreescu; M Cushman; J M Hammond; M E Wood
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.

Authors:  F Schiele; F Lindgaerde; H Eriksson; J P Bassand; A Wallmark; P O Hansson; G Grollier; M Sjo; M Moia; A Camez; V Smyth; M Walker
Journal:  Thromb Haemost       Date:  1997-05       Impact factor: 5.249

3.  Mechanism of action and monitoring of anticoagulants.

Authors:  J Hirsh
Journal:  Semin Thromb Hemost       Date:  1986-01       Impact factor: 4.180

Review 4.  The development of hirudin as an antithrombotic drug.

Authors:  F Markwardt
Journal:  Thromb Res       Date:  1994-04-01       Impact factor: 3.944

5.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

Authors:  J I Weitz; M Hudoba; D Massel; J Maraganore; J Hirsh
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

6.  Monitoring warfarin therapy in patients with lupus anticoagulants.

Authors:  S Moll; T L Ortel
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

Review 7.  Heparin-induced thrombocytopenia: natural history, diagnosis, and management.

Authors:  S R Deitcher; T L Carman
Journal:  Vasc Med       Date:  2001       Impact factor: 3.239

8.  How to use low-molecular weight heparin for outpatient management of deep vein thrombosis.

Authors:  S R Deitcher; J W Olin; J Bartholomew
Journal:  Cleve Clin J Med       Date:  1999-06       Impact factor: 2.321

9.  A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.

Authors:  F Schiele; A Vuillemenot; P Kramarz; Y Kieffer; J Soria; C Soria; A Camez; M C Mirshahi; J P Bassand
Journal:  Thromb Haemost       Date:  1994-05       Impact factor: 5.249

10.  A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia.

Authors:  M D Tarantino; S M Curtis; G S Johnson; J S Waye; M A Blajchman
Journal:  Am J Hematol       Date:  1999-02       Impact factor: 10.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.